Targeting a Group of Rare Tumors
A molecularly targeted therapeutic has been approved by the FDA for the treatment of tenosynovial giant cell tumors. Learn more.
Progress Against Cancer
A molecularly targeted therapeutic has been approved by the FDA for the treatment of tenosynovial giant cell tumors. Learn more.
The FDA approved pembrolizumab, in immunotherapy called a checkpoint inhibitor, to treat certain patients with esophageal cancer.
A new antihormone agent has been approved to treat men with nonmetastatic prostate cancer that has stopped responding to standard antihormone treatments.
A molecularly targeted therapeutic has been approved for treating certain patients with multiple myeloma. Learn more about this recently approved therapy.
An immunotherapeutic known as a checkpoint inhibitor has been approved for the treatment of certain patients with small-cell lung cancer.
A molecularly targeted therapeutic has been approved to treat some patients with diffuse large B-cell lymphoma the most common type of non-Hodgkin lymphoma.
A combination of an immunotherapy and a molecularly targeted therapy has been approved to treat patients with advanced renal cell carcinoma, kidney cancer.
A molecularly targeted therapeutic has been approved for use in combination with fulvestrant for treating certain men and women with breast cancer.
A combination of an immunotherapy and a targeted therapeutic recently was approved by the FDA for patients advanced renal cell carcinoma (kidney cancer).
A molecularly targeted therapeutic was approved by the FDA to treating certain patients with urothelial carcinoma, the most common form of bladder cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More